Publication summary

This paper evaluates the diverse sources of data in LMICs that could be used to bridge the gap between now and the time when public-sector surveillance capacity is established. Data generation and sharing are key challenges in the global surveillance of drug-resistant infections. The challenge is greater in poor resource settings of low and middle-income countries (LMICs) where capacity is insufficient to meet the demand. While there have been several initiatives to strengthen the way we use surveillance to inform actions to tackle AMR, the routine generation of reliable data will take time to establish.

Who this is for

  • Policymakers and civil servants working in AMR
  • Academic researchers
  • Pharmaceutical industry
  • Public health professionals and health care administrators
  • Laboratory professionals

Key findings

  • Examining the strengths and weaknesses of data from private and public organisations
  • Highlighting what are the barriers to using alternative sources of antimicrobial resistance (AMR) data to inform policy-making
  • Explaining what innovation is required to effectively harness AMR data

Access via 'The National Center for Biotechnology Information'